Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Transthyretin Amyloidosis Treatment Market Report 2024

Transthyretin Amyloidosis Treatment Global Market Report 2025 – By Type (Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)), By Drug (Tafamidis, Patisiran, Inotersen, Other Drugs), By Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

Transthyretin Amyloidosis Treatment Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Transthyretin Amyloidosis Treatment Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Transthyretin Amyloidosis Treatment Market Definition

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body's organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR).

The main types of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Transthyretin amyloidosis with polyneuropathy (ATTR-PN) refers to a type of amyloidosis characterized by the deposition of abnormal transthyretin protein in nerves, leading to peripheral neuropathy and other neurological symptoms. These disease types are treated with drugs such as tafamidis, patisiran, inotersen, and others, along with targeted therapy, supportive therapy, and pipeline therapies, which are distributed through channels including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.

Transthyretin Amyloidosis Treatment Market Segmentation

The transthyretin amyloidosis treatment market covered in this report is segmented –

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN

2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Transthyretin Amyloidosis Treatment Market Size and growth rate 2025 to 2029: Graph

Transthyretin Amyloidosis Treatment Market Size 2025 And Growth Rate

The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.

Transthyretin Amyloidosis Treatment Market Growth Forecast

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.

Book your 30 minutes free consultation with our research experts

Contact Us

Transthyretin Amyloidosis Treatment Market Driver: Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market

Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment market.

Transthyretin Amyloidosis Treatment Market Driver: Aging Population Demographics Fuel Growth In Transthyretin Amyloidosis Treatment Market

The rising aging population demographic is expected to propel the growth of the transthyretin amyloidosis treatment market going forward. An aging population refers to a demographic shift in which the median age of a population increases due to declining fertility rates and rising life expectancy. Aging is a significant risk factor for transthyretin amyloidosis (ATTR), and as the population ages, there is a higher prevalence of Transthyretin Amyloidosis cases. This leads to a growing patient pool in need of treatment. For instance, in October 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, every country in the world is experiencing growth in both the size and proportion of older persons in the population, and by 2030, 1 in 6 people in the world will be aged 60 years or over. Therefore, the rising demographics of the aging population are driving the growth of the transthyretin amyloidosis treatment market.

Global Transthyretin Amyloidosis Treatment Market Major Players

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Global Transthyretin Amyloidosis Treatment Market Trend: Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment

Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022. `

Transthyretin Amyloidosis Treatment Market Merger And Acquisition: Bridgebio And Bayer Partner To Treat ATTR-CM In Europe

In April 2024, BridgeBio Pharma, a US-based biotech company, collaborated with Bayer. This partnership aimed at treating transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. Under the deal, Bayer will exclusively commercialize the drug, with BridgeBio receiving up to $310 million in payments and royalties. This collaboration enhances the potential availability of acoramidis for patients suffering from this serious condition. Bayer is a Germany-based Life Science company.

Regional Outlook For The Global Transthyretin Amyloidosis Treatment Market

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the transthyretin amyloidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Transthyretin Amyloidosis Treatment Market?

The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Transthyretin Amyloidosis Treatment Industry?

The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloidosis treatment market statistics, including transthyretin amyloidosis treatment industry global market size, regional shares, competitors with a transthyretin amyloidosis treatment market share, detailed transthyretin amyloidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. This transthyretin amyloidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

Transthyretin Amyloidosis Treatment Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $5.95 billion
Revenue Forecast In 2034 $8.04 billion
Growth Rate CAGR of 7.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Transthyretin Amyloidosis Treatment Market Characteristics

    3. Transthyretin Amyloidosis Treatment Market Trends And Strategies

    4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Transthyretin Amyloidosis Treatment Growth Analysis And Strategic Analysis Framework

    5.1. Global Transthyretin Amyloidosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Transthyretin Amyloidosis Treatment Market Growth Rate Analysis

    5.4. Global Transthyretin Amyloidosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Transthyretin Amyloidosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Transthyretin Amyloidosis Treatment Total Addressable Market (TAM)

    6. Transthyretin Amyloidosis Treatment Market Segmentation

    6.1. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN)

    Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

    6.2. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Tafamidis

    Patisiran

    Inotersen

    Other Drugs

    6.3. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Targeted Therapy

    Supportive Therapy

    Pipeline Therapy

    6.4. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Specialty Pharmacies

    Retail Pharmacies

    Online Pharmacies

    6.5. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Early-Stage ATTR-PN

    Advanced-Stage ATTR-PN

    6.6. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Mild ATTR-CM

    Moderate ATTR-CM

    Severe ATTR-CM

    7. Transthyretin Amyloidosis Treatment Market Regional And Country Analysis

    7.1. Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Transthyretin Amyloidosis Treatment Market

    8.1. Asia-Pacific Transthyretin Amyloidosis Treatment Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Transthyretin Amyloidosis Treatment Market

    9.1. China Transthyretin Amyloidosis Treatment Market Overview

    9.2. China Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Transthyretin Amyloidosis Treatment Market

    10.1. India Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Transthyretin Amyloidosis Treatment Market

    11.1. Japan Transthyretin Amyloidosis Treatment Market Overview

    11.2. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Transthyretin Amyloidosis Treatment Market

    12.1. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Transthyretin Amyloidosis Treatment Market

    13.1. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Transthyretin Amyloidosis Treatment Market

    14.1. South Korea Transthyretin Amyloidosis Treatment Market Overview

    14.2. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Transthyretin Amyloidosis Treatment Market

    15.1. Western Europe Transthyretin Amyloidosis Treatment Market Overview

    15.2. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Transthyretin Amyloidosis Treatment Market

    16.1. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Transthyretin Amyloidosis Treatment Market

    17.1. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Transthyretin Amyloidosis Treatment Market

    18.1. France Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Transthyretin Amyloidosis Treatment Market

    19.1. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Transthyretin Amyloidosis Treatment Market

    20.1. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Transthyretin Amyloidosis Treatment Market

    21.1. Eastern Europe Transthyretin Amyloidosis Treatment Market Overview

    21.2. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Transthyretin Amyloidosis Treatment Market

    22.1. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Transthyretin Amyloidosis Treatment Market

    23.1. North America Transthyretin Amyloidosis Treatment Market Overview

    23.2. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Transthyretin Amyloidosis Treatment Market

    24.1. USA Transthyretin Amyloidosis Treatment Market Overview

    24.2. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Transthyretin Amyloidosis Treatment Market

    25.1. Canada Transthyretin Amyloidosis Treatment Market Overview

    25.2. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Transthyretin Amyloidosis Treatment Market

    26.1. South America Transthyretin Amyloidosis Treatment Market Overview

    26.2. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Transthyretin Amyloidosis Treatment Market

    27.1. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Transthyretin Amyloidosis Treatment Market

    28.1. Middle East Transthyretin Amyloidosis Treatment Market Overview

    28.2. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Transthyretin Amyloidosis Treatment Market

    29.1. Africa Transthyretin Amyloidosis Treatment Market Overview

    29.2. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Transthyretin Amyloidosis Treatment Market Competitive Landscape And Company Profiles

    30.1. Transthyretin Amyloidosis Treatment Market Competitive Landscape

    30.2. Transthyretin Amyloidosis Treatment Market Company Profiles

    30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

    31. Transthyretin Amyloidosis Treatment Market Other Major And Innovative Companies

    31.1. GSK Plc

    31.2. Novo Nordisk A/S

    31.3. Merck & Co. Inc

    31.4. Astellas Pharma Inc.

    31.5. Alexion Pharmaceuticals Inc.

    31.6. Alnylam Pharmaceuticals Inc

    31.7. PTC Therapeutics

    31.8. Ionis Pharmaceuticals

    31.9. Prothena Corporation plc

    31.10. BridgeBio Pharma Inc.

    31.11. Sorrento Therapeutics Inc.

    31.12. Intellia Therapeutics

    31.13. Akcea Therapeutics Inc.

    31.14. Eidos Therapeutics Inc

    31.15. Acrotech Biopharma Inc

    32. Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market

    34. Recent Developments In The Transthyretin Amyloidosis Treatment Market

    35. Transthyretin Amyloidosis Treatment Market High Potential Countries, Segments and Strategies

    35.1 Transthyretin Amyloidosis Treatment Market In 2029 - Countries Offering Most New Opportunities

    35.2 Transthyretin Amyloidosis Treatment Market In 2029 - Segments Offering Most New Opportunities

    35.3 Transthyretin Amyloidosis Treatment Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Pfizer Inc Financial Performance
  • Table 78: Abbvie Inc Financial Performance
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: Bristol Myers Squibb Company Financial Performance
  • Table 81: AstraZeneca plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Pfizer Inc Financial Performance
  • Figure 78: Abbvie Inc Financial Performance
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: Bristol Myers Squibb Company Financial Performance
  • Figure 81: AstraZeneca plc Financial Performance

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

Read More

How Will The Nuclear Medicine Market Grow In 2022?

Read More

What Is The Pediatric Imaging Market Overview In 2022?

Read More

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the clinical chemistry market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth

Read More

Pediatric Bladder Treatment Global Market Report 2025 – By Type (Diurnal Incontinence, Enuresis, Other Types), By Treatment (Urotherapy, Medication, Surgical Reconstruction, Other Treatments), By Route of Administration (Oral, Parenteral, Other Route of Administrations), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Reversible Airway Diseases Treatment Global Market Report 2025 – By Treatment  (Chest X Ray, Computed Tomography (CT) Scan, Lung Therapies, Surgery Transplant, Medications), By Diseases (Asthma, Chronic Bronchitis, Emphysema, Cystic Fibrosis, Bronchiolitis, Other Diseases), By End-Users (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Urothelial Carcinoma Treatment Global Market Report 2025 – By Type (Non-Invasive Urothelial Carcinoma Treatment, Invasive Urothelial Carcinoma Treatment), By Treatment (Immunotherapy, Radiotherapy, Chemotherapy), By Cancer Type (Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer), By End-Users (Hospitals, Homecare, Specialty Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Mineral And Bone Disorder Treatment Global Market Report 2025 – By Treatment (Diet, Nutrition, Medication, Supplements, Dialysis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Neurotrophic Keratitis Treatment Global Market Report 2025 – By Treatment (Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments), By Route of Administration (Oral, Topical, Other Routes of Administration), By Application (Stage I, Stage II, Stage III), By End-User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Anorectal Disorders Treatment Global Market Report 2025 – By Treatment (Drugs, Surgery, Other Treatment), By Disease (Diarrhea, Hemorrhoid, Abscesse, Fistula, Itching, Other Disease), By Route Of Administration (Oral, Parenteral, Rectal, Other Route of administration), By End-Users (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Aspergillosis Treatment Global Market Report 2025 – By Type (Allergic Aspergillosis, Chronic Aspergillosis, Invasive Aspergillosis, Other Type), By Drug Class (Corticosteroids, Antifungal drugs, Other Drug Class), By Route of Administration (Oral, Injectable, Other Route Of Administration), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Other Distribution Channel) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Histoplasmosis Treatment Global Market Report 2025 – By Drug Type (Amphotericin B, Itraconazole, Ketoconazole, Other Drug Type), By Mode of Administration (Injectable, Oral, Other Mode Of Administration), By Patient Type (Pediatric, Adult), By End-User (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Transthyretin Amyloidosis Treatment market?

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body's organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR). For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here

How will the Transthyretin Amyloidosis Treatment market drivers and restraints affect the market dynamics? What forces will shape the Transthyretin Amyloidosis Treatment industry going forward?

The Transthyretin Amyloidosis Treatment market major growth driver - Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market. For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here

What is the forecast market size or the forecast market value of the Transthyretin Amyloidosis Treatment market?

The Transthyretin Amyloidosis Treatment market size has grown strongly in recent years. The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research. The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines. For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here

How is the Transthyretin Amyloidosis Treatment market segmented?

The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here

Which region has the largest share of the Transthyretin Amyloidosis Treatment market? What are the other regions covered in the report?

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here.

Who are the major players in the Transthyretin Amyloidosis Treatment market?

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A. For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here.

What are the key trends in the Transthyretin Amyloidosis Treatment market?

Major trends in the Transthyretin Amyloidosis Treatment market include Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment. For further insights on the Transthyretin Amyloidosis Treatment market, request a sample here.

What are the major opportunities in the Transthyretin Amyloidosis Treatment market? What are the strategies for the Transthyretin Amyloidosis Treatment market?

For detailed insights on the major opportunities and strategies in the Transthyretin Amyloidosis Treatment market, request a sample here.

How does the Transthyretin Amyloidosis Treatment market relate to the overall economy and other similar markets?

For detailed insights on Transthyretin Amyloidosis Treatment's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Transthyretin Amyloidosis Treatment industry?

For detailed insights on the mergers and acquisitions in the Transthyretin Amyloidosis Treatment industry, request a sample here.

What are the key dynamics influencing the Transthyretin Amyloidosis Treatment market growth? SWOT analysis of the Transthyretin Amyloidosis Treatment market.

For detailed insights on the key dynamics influencing the Transthyretin Amyloidosis Treatment market growth and SWOT analysis of the Transthyretin Amyloidosis Treatment industry, request a sample here.